Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20166584 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL9498219 | 0.83 | TSHR (0.54) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL20514025 | 0.82 | GAA (0.58) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL20514178 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL19551054 | 0.81 | ITGB1 (0.50) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL19550575 | 0.81 | ITGB1 (0.50) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL19550572 | 0.81 | ITGB1 (0.50) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL20177562 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDKMT2AMEN1KDM4E | |
| SCHEMBL20166339 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDKMT2AKDM4ERAB9A | |
| SCHEMBL9498080 | 0.79 | TSHR (0.57) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3541804-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093577-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093577-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | SMN1; SMN2 4642/4885HPGD 1533/4885KMT2A 4489/4885 |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | SMN1; SMN2 4642/4885HPGD 1533/4885KMT2A 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.